NeuroStar® Software Upgrades Innovate Patient Engagement

NeuroStar® Transforms Patient Care with Advanced Software Upgrades

Neuronetics, Inc. (NASDAQ: STIM), based in Malvern, Pennsylvania, is at the cutting edge of medical technology aimed at enhancing quality of life for patients facing neurohealth disorders. The company recently unveiled significant improvements to its NeuroStar Advanced Therapy and the proprietary TrakStar patient data management software. These enhancements are designed to boost patient communication, streamline clinical data management, and fortify cybersecurity measures.

Cory Anderson, Senior Vice President of Research and Development and Clinical, emphasized the impact of these upgrades: “We’re not just enhancing technology; we’re transforming how practices care for patients.” He shared that the latest features in the NeuroStar System and TrakStar are geared towards empowering providers with tools that enable more personalized, efficient, and secure treatment options for patients battling depression.

Key Features of the Software Enhancements

The recent software advancements provide NeuroStar practices with vital tools that not only improve patient care but also optimize operational efficiency. Here’s a deep dive into the key upgrades:

Enhanced Patient Communication

One of the standout features is the new CRM abilities that automate SMS and email communications. This advancement allows for personalized guidance during the initial phases of NeuroStar treatment. Furthermore, secure uploads of insurance cards streamline claims processing, significantly reducing potential errors from manual entry. For multi-site practices, the ability to filter communications by location ensures patient needs are effectively managed at a local level.

Expanded TrakStar Survey Options

Another noteworthy enhancement is the expanded range of automated clinical surveys now available to practices. This feature enables continuous monitoring of patient well-being during and post-treatment, allowing for real-time insights that can help in tailoring care effectively.

Advanced Clinical Data Capture

With the internet-connected NeuroStar device, critical clinical information can now be synchronized with the TrakStar data management system. This valuable upgrade secures automated tracking and improves the accuracy of data collection, further enhancing the quality of patient care.

Improved Security Measures

Neuronetics is dedicated to patient safety, exemplified by the proactive updates to the operating system incorporated in these software upgrades. These updates are essential for safeguarding patient data and ensuring encrypted communications are upheld consistently.

Availability and Impact

Currently, the updated TrakStar software is accessible to all cloud-based NeuroStar providers, while the NeuroStar System software updates are being rolled out in phases throughout the year. These enhancements are set to revolutionize how practices interact with patients, as well as improve the overall treatment experience.

About Neuronetics

Neuronetics, Inc. holds a firm belief that mental health is paramount, just as much as physical health. As a leader in the field of neuroscience, Neuronetics is redefining expectations for both patients and healthcare providers with its NeuroStar Advanced Therapy. This innovative, noninvasive treatment aims to improve the quality of life for those who struggle with neurohealth conditions when conventional medication may not provide relief.

NeuroStar therapy is recognized for its efficacy in treating depressive episodes and alleviating anxiety symptoms in adults suffering from Major Depressive Disorder (MDD) who have not achieved satisfactory results from previous antidepressants. Additionally, it is FDA-cleared for use as an adjunct treatment for adults with obsessive-compulsive disorder, as well as for adolescents aged 15-21 with MDD. With over 6.6 million treatments delivered, NeuroStar Advanced Therapy is leading the way in TMS treatment for MDD among adults.

Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

Frequently Asked Questions

What new features have been added to NeuroStar® software?

The latest NeuroStar® software upgrades include enhanced patient communication, expanded survey options, advanced clinical data capture, and improved security measures.

How will these software upgrades impact patient care?

These upgrades are designed to improve communication, streamline operations, and enhance the overall treatment experience for patients receiving NeuroStar therapy.

Is the upgraded TrakStar software available immediately?

Yes, the updated TrakStar software is available now for all cloud-based NeuroStar providers.

What does NeuroStar® therapy involve?

NeuroStar® therapy is a non-drug, noninvasive treatment option for individuals with neurohealth conditions that aims to improve quality of life.

Who is eligible for NeuroStar® treatment?

NeuroStar® is indicated for adults with Major Depressive Disorder (MDD) who have not found relief through traditional medication, and for adolescents aged 15-21 with MDD.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.